scholarly journals Pathobiological behavior and molecular mechanism of signet ring cell carcinoma and mucinous adenocarcinoma of the stomach: A comparative study

2004 ◽  
Vol 10 (5) ◽  
pp. 750 ◽  
Author(s):  
Xue-Fei Yang
2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 58-58 ◽  
Author(s):  
R. Thota ◽  
T. Tashi ◽  
W. Gonsalves ◽  
V. Murukesan ◽  
P. Townley ◽  
...  

58 Background: Signet ring cell carcinoma accounts for less than 1% of all colon cancers. We examined the clinical pathological features and prognosis of signet ring cell carcinoma of colon and compare it with mucinous and non-mucinous adenocarcinoma of colon. Methods: A total of 206 patients diagnosed with signet ring cell carcinoma from 1995 to 2009 were identified from the VA Central Cancer Registry (VACCR) database. Age, race, histology, grade, lymph node status, stage and type of treatment received data were collected. Results: Out of 206 patients, 173 (83.9%) were white, 31 (15%) were black, and 2 patients were listed as unknown. Median age of diagnosis was 67 years as compared to 70 years for both mucinous and non-mucinous adenocarcinoma of colon. Pathological T-stages were as follows: T1 = 2.9%, T2=5.3%, T3=33.9%, T4= 25.7%, and unknown 32%. Of the total, 22.3% were located in caecum, 21.8% in ascending colon, 15.5% in sigmoid colon, 7.7% in appendix and hepatic flexure of colon, 11.1% in transverse colon, 2.9% in splenic flexure and 4.4% in descending colon. 33.5% were lymph node positive, 34.6% were lymph node negative, and 31.8% were unknown. Histologically grade 3 (55.4%) was most commonly reported followed by grade 2 (7.3%), grade 1 (2.5%), grade 4 (1.9%)and in 33% grade was unknown. 41.3% patients received only surgery while 34% received surgery with adjuvant chemotherapy, 7.3% received chemotherapy alone and 7.8% patients received either chemotherapy, radiation or hormonal therapy alone, 9% did not receive any therapy. 1 year, 3 year and 5 year survivals for signet ring cell cancer compared to adeno carcinoma was 60% vs 80%, 33% vs 60%, and 24% vs 47% respectively. Median survival of signet ring cell carcinoma compared to mucinous and non mucinous adenocarcinoma was 19 months, 48 months and 62 months respectively. Conclusions: Signet ring cell carcinoma of colon has poor survival rates than the other histological subtypes. Signet ring cell carcinoma presents at an earlier age, higher tumor grade and advanced stage at diagnosis when compared to mucinous and non-mucinous adenocarcinoma of colon. Due to rarity of this disease further multi-institute studies are required for in-depth understanding and analysis of this disease. No significant financial relationships to disclose.


2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3608-3608
Author(s):  
Jianwei Zhang ◽  
Yanhong Deng ◽  
Yue Cai ◽  
Huabin Hu ◽  
Zehua Wu ◽  
...  

3608 Background: Mucinous adenocarcinoma and signet-ring cell carcinoma were uncommon in locally advanced rectal cancer. And it has been reported that both mucinous adenocarcinoma and signet-ring cell carcinoma showed poor response to standard neoadjuvant chemoradiotherapy. Here, we tried to compare the efficacy of different neoadjuvant treatment regimen on locally advanced rectal mucinous adenocarcinoma or signet-ring cell carcinoma (M/S). Methods: We enrolled patients with locally advanced rectal cancer from 3 prospective clinical trials (NCT01211210, NCT02217020 and NCT02887313), including FOWARC study (N = 309), mFOLFOXIRI neoadjuvant chemotherapy trial (N = 103) and the total neoadjuvant treatment with FOLFOX and radiotherapy (N = 129). Among the 541 patients, 41 (7.6%) patients were M/S and 500 were non-M/S. Totally, 7 M/S patients and 84 non-M/S patients received 5FU concurrent with radiotherapy (Group A), 20 M/S patients and 208 non-M/S underwent FOLFOX concurrent with radiation or total neoadjuvant treatment (Group B), 11 M/S patients and 92 non-M/S patients underwent mFOLFOXIRI neoadjuvant chemotherapy alone (Group C). Other 3 M/S patients and 116 non-M/S patients received FOLFOX neoadjuvant chemotherapy alone (Group D). Results: Among M/S patients, only 4 (9.7%) achieved pathologic complete response (pCR), and 6 (14.6%) patients had tumor downstaging to ypstage 0-I. In group A, the pCR rate was 14.3% and 11.9% (p = 0.85), and the tumor downstaging rate was 14.3% and 36.9% (p = 0.22) in M/S and non-M/S patients, respectively. In group B, the pCR rate was 15.0% and 34.6% (p = 0.07), and the tumor downstaging rate was 25.0% and 60.1% (p = 0.002) in M/S and non-M/S patients, respectively. However, in group C and group D with chemotherapy alone as neoadjuvant treatment, no M/S patients showed pCR or tumor downstaging; while in non-M/S patients higher tumor downstaging rate was observed. Conclusions: M/S showed resistance to neoadjuvant chemotherapy along regimens. Even with chemoradiotherapy, M/S patients showed poorer response than that of non/M/S patients. Further study was warranted to explore the new regimen for M/S patients. [Table: see text]


2021 ◽  
Author(s):  
Qinghua Wang ◽  
Hongjuan Zheng ◽  
Xiaoxiao Chen ◽  
Xia Zhang ◽  
Xiayun Jin ◽  
...  

Abstract Purpose: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Approximately 25% of patients with AJCC stage II suffered recurrence after radical surgery, but the role of adjuvant chemotherapy in Stage II CRC is controversial. We aimed to evaluate the benefit from chemotherapy for T3N0M0 patients with adverse histological features. Methods: An analysis of the Surveillance, Epidemiology, and End Results (SEER) 18 databases was performed to identify patients underwent radical resection 20-80 years old with colonic carcinoma diagnosed during year 2004 to 2012. Poorly differentiated, undifferentiated, mucinous adenocarcinoma and signet ring cell carcinoma (SRCC) were defined as adverse histological features, and well or moderately differentiated adenocarcinoma as good histological features. Multivariate analyses were used to adjust the effects of other covariates. The survival benefit of adjuvant chemotherapy was demonstrated in the propensity score matching cohort. Results: The adjuvant chemotherapy brought no survival benefit (good histological features HR, 1.076; 95% CI, 0.957-1.211; P=0.220; adverse histological features HR, 0.995; 95% CI, 0.777-1.274; P=0.967); Neither mucinous adenocarcinoma nor signet ring cell carcinoma brought a significance on survival (mucinous adenocarcinoma HR, 0.699; 95% CI, 0.488-1.002; P=0.051; signet ring cell carcinoma HR, 0.750; 95% CI, 0.386-1.459; P=0.397) compared to adenocarcinoma. Left-side colon was associated with a poorer survival in good histological features group (HR, 1.136; 95% CI, 1.034-1.248; P=0.008). Conclusions: The adverse histological features don’t influence on survival for patients with T3N0M0 staging, and adjuvant chemotherapy is invalid to improve the survival for these patients, indicating adverse histological features alone was not sufficient for decision of adjuvant chemotherapy in this situation rather than the recommendation of the guidelines.


2021 ◽  
Vol 12 (7) ◽  
pp. 1122-1125
Author(s):  
Alberto Testori ◽  
Gianluca Perroni ◽  
Camilla De Carlo ◽  
Alessandro Crepaldi ◽  
Marco Alloisio ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document